Photo via New York Post

Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition

Read the original at New York Post ↗
Cite

Associated Press. (2026, October 29). Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition. New York Post. https://nypost.com/2026/10/29/health/trump-admin-eases-access-to-unproven-peptides-favored-by-rfk-jr-despite-fda-opposition/

Dated from the outlet's own feed. Check the original for its byline.

New York Post · collected 2026-10-29 · by Associated Press

Quick Summary

The Trump administration recently relaxed regulations to allow easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., despite opposition from the FDA’s scientific staff. The Department of Health and Human Services draft policy targets specific peptides used for wellness purposes such as muscle building and injury healing, allowing specialty pharmacies to sell them without facing legal action from the FDA. This move faces criticism from FDA drug staffers who fear it could compromise public safety by undermining the agency's role in regulating unapproved drugs.
Written by AI on 2026-10-31, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

As of October 28, 2026, the Trump administration's Department of Health and Human Services (HHS) allowed pharmacies to produce and sell six unapproved peptide drugs without FDA approval. This decision faced significant opposition from most FDA scientific staff members who warned it could undermine public health by exposing Americans to potentially unsafe substances. HHS stated that this move is intended to provide a regulated alternative for consumers seeking peptides, which have previously been available through the "gray market," often imported illegally from countries like China. The policy will be in effect while HHS works on formalizing a rule change and is set to take comments for two weeks before finalization.

Written for “RFK Jr Eases Access To Unapproved Peptides” on 2026-11-21, grounded in this article and the 13 other(s) covering the same event.

How they differ

11 outlets covered “RFK Jr Eases Access To Unapproved Peptides”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

New York PostThis outlet29 Oct

The Trump administration recently relaxed regulations to allow easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., despite opposition from the FDA’s scientific staff. The Department of Health and Human Services draft policy targets specific peptides used for wellness purposes such as muscle building and injury healing, allowing specialty pharmacies to sell them without facing…

Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition (this article)
CBS News29 Oct

Adam Yamaguchi reports on Robert F. Kennedy Jr.’s efforts to encourage pharmacies to manufacture peptides that have not been approved by the FDA. The article focuses specifically on RFK Jr.’s advocacy for these unregulated substances, which are being promoted despite lacking official approval from regulatory authorities.

Inside RFK Jr.'s push for pharmacies to make non-FDA approved peptides →3 articles from CBS News on this story
ABC News (US)29 Oct

HHS announced that some wellness peptides will be available by prescription. The department will temporarily allow compounding pharmacies to provide six specific peptides through prescriptions. This announcement was made on October 29, 2026.

WATCH: HHS says some wellness peptides will be available by prescription →2 articles from ABC News (US) on this story
NBC News28 Oct

The Department of Health and Human Services has temporarily allowed compounding pharmacies to manufacture six unapproved peptides without legal repercussions while the FDA formalizes new rules for their production. These peptides include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which are marketed as treatments for various health conditions but lack FDA approval due to insufficient safety and efficacy data…

RFK Jr. takes shortcut to make some peptides more widely available →
Toronto Star28 Oct

FDA scientific staff largely opposed a Trump administration plan aimed at easing access to unproven peptide drugs, despite pushback from Health Secretary Robert F. Kennedy Jr. This policy would allow specialty pharmacies to sell peptides without the FDA's rigorous safety and effectiveness review process, which are currently considered illegal drugs. Most FDA drug staffers warned that this could undermine the…

FDA scientists opposed the Trump administration's move to ease peptides access →
The Guardian28 Oct

FDA scientific staff members opposed a Trump administration plan pushed by Health Secretary Robert F Kennedy Jr, which aimed to ease access to unproven peptide drugs in the US wellness industry. The policy, posted online by HHS on Wednesday, would allow specialty pharmacies to sell several peptides without FDA approval, despite warnings from FDA scientists about potential safety risks. This move faces significant…

FDA scientists opposed Trump administration’s move to ease peptide access →
Show 5 more outlets
Time28 Oct

The U.S. Department of Health and Human Services announced on October 28 that it will not take enforcement action against licensed pharmacists who dispense six unapproved peptides to consumers. These peptides include BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, which are short chains of amino acids injected for various health benefits, despite scientific uncertainty about their safety and efficacy. The policy…

The Peptide Rush Has Begun →
NPR29 Oct

The Trump administration's Department of Health and Human Services plans to relax restrictions on six unproven peptides, allowing small compounding pharmacies to produce them despite lacking FDA approval. This policy change supports wellness influencers and some clinicians who promote these peptides for various health issues like ulcerative colitis and insomnia, though evidence of their safety and effectiveness is…

Trump administration will allow pharmacies to make popular peptides →
The Independent29 Oct

Health Secretary Robert F. Kennedy Jr. announced a new policy allowing the widespread use of six unapproved peptide compounds, despite the FDA advising against their use due to potential risks. The Health and Human Services Department will not take enforcement action against those selling these peptides, arguing that easing access will provide patients with controlled alternatives while protecting safety through…

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them →
BBC29 Oct

US Health Secretary Robert F Kennedy Jr has announced plans to relax restrictions on six unapproved peptides through compounding pharmacies, despite warnings from health experts about their potential risks due to insufficient human clinical trials and unknown long-term side effects. The draft regulation was published in the US Federal Register and will undergo a public comment period following its official…

US Health Secretary RFK Jr to expand access to unapproved peptides →
Reason29 Oct

HHS has established a new policy allowing pharmacies to produce and sell six specific peptides without FDA approval, aiming to provide a safer alternative to purchasing these substances from unregulated foreign sources. The decision is seen as a victory for peptide advocates and reflects frustration with FDA's slow processes, despite the lack of formal FDA endorsement or safety reviews for compounded drugs.

RFK Jr. Institutes Backdoor Approval of 6 Peptides →

Where they agree and split

Framing

How the first headlines put it

Attributed to a source2
Stated as fact7
The headlines (9)

Some wellness peptides will become widely available, HHS says ABC News · attributed to a source

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them The Independent · attributed to a source

RFK Jr. takes shortcut to make some peptides more widely available NBC News · stated as fact

FDA scientists opposed the Trump administration's move to ease peptides access Toronto Star · stated as fact

FDA scientists opposed Trump administration’s move to ease peptide access The Guardian · stated as fact

The Peptide Rush Has Begun Time · stated as fact

Trump administration will allow pharmacies to make popular peptides NPR · stated as fact

Dr. Jon LaPook explains why peptide sales are controversial CBS News · stated as fact

US Health Secretary RFK Jr to expand access to unapproved peptides BBC · stated as fact

The full story: what happened, how it changed, and all 14 articles →

Compared with similar articles

This article reads unscored and hedges 13% of its claims. Each row says how that neighbour differs.
BBC News
Leans right Hedges 1 of 20 claims Outlet record 65/100
Toronto Star
Leans left Hedges 5 of 33 claims Outlet record 64/100
ABC News (US)
Hedges 2 of 14 claims Outlet record 66/100
CBS News
Hedges 3 of 22 claims Outlet record 66/100
The Guardian
Leans left Hedges 4 of 30 claims Outlet record 64/100
NBC News
Hedges 4 of 19 claims Outlet record 77/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
NPR
Leans right Hedges 4 of 30 claims Outlet record 60/100
CBS News
Centre Hedges 1 of 3 claims Outlet record 66/100
The Independent
Hedges 1 of 12 claims Outlet record 59/100

Story

RFK Jr Eases Access To Unapproved Peptides
Politics · 14 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
46
sentences that state something as happening or true
Uncertain
13%
6 of 46 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
66/100
New York Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
14
Politics
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-31 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

New York Post · 21706 article(s) · 41 correction(s) detected
Running correction rate · 41 correction(s)

Who wrote this

Associated Press
804 article(s) here · 1 carrying a prediction
Agrochemical maker Bayer will pay up to $7.25 billion over two decades to resolve thousands of claims from U.S. cancer patients asserting the company should have warned people that its popular weed killer Roundup could cause lymphoma, according to a settlement approved Friday by a Missouri judge.
The fourth-round pick from Clemson would make his first NFL start if Smith can’t go, but that doesn't appear to be the case this week.
Journalists and observers reported delays of more than 30 minutes before being able to enter the death chamber where Dennes’ final statements would be read and the execution would take place.
The legislation’s sweeping changes would shorten the timeline to start big energy projects and make sure data centers pay for the energy they use.
Published Nov. 20, 2026, 4:22 a.m. ET Russia launched missiles and drones across Kyiv overnight that killed three people, injured nine others and damaged bridges and transport infrastructure, local authorities said Friday. “We will respond to these attacks, and I want everyone to be clear about that,” Putin told reporters Thursday in China, where he attended a summit with the Chinese and US presidents.
Published Nov. 19, 2026, 10:16 p.m. ET The U.S. Army decided to delay Friday’s detonation of several tons of bomb-making chemicals in southeast Iowa after an outpouring of public concern that a cloud of lead dust could cause environmental contamination and health problems.
Kirsten Davies, chief information officer at the Defense Department, will fill the role, according to social media posts by several members of Trump’s cabinet.
Employees cannot realistically opt out of reading emails from their agency director, and the messages could coerce them to hide their own faith or feel pressure to adopt Rollins’ Christian faith, Thompson ruled.
Reinaldo Dennes, 70, was set to receive a lethal injection about an hour later at a prison in Texas and become the ninth person executed by that state this year.
Plans by the US army to detonate about 5 tons of bomb-making chemicals that have become unusable and might explode if moved have residents in south-east Iowa worried that a cloud of lead dust could cause environmental contamination and health problems.
Wire or desk byline, not an individual reporter.
Also by Associated Press
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 804 articles by Associated Press →

Topics

Associated Press FDA HHS Health WASHINGTON

Subjects

FDA ORG · 9× Kennedy PERSON · 5× HHS ORG · 3× Trump PERSON · 2× Associated Press ORG · 1× Food and Drug Administration ORG · 1× Health ORG · 1× RFK Jr. PERSON · 1× Robert F. Kennedy Jr. PERSON · 1× WASHINGTON GPE · 1×

Narrative

Decisions over compounding have long rested with the FDA, not HHS Decisions about regulating peptides and compounding pharmacies have almost always come from the FDA, which has an office dedicated to protecting US consumers from unsafe or poor-quality compounded drugs.
framing: assertive · carried by 1 article(s) · first seen 2026-10-31
The government will take comments for two weeks before finalizing the measure.

Claims (46 extracted, 6 hedged)

Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition asserted
admin → ease → opposition
The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. asserted
administration → act → drugs
Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development. uncertain
staffers → have → development
The draft policy posted online by Kennedy’s Department of Health and Human Services covers a handful of injectable peptides promoted within the wellness industry for uses such as building muscle, healing injuries and boosting energy. asserted
policy → post → energy
The government will take comments for two weeks before finalizing the measure. asserted
government → take → measure
The document, primarily written by officials at HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s long-standing mission of keeping unsafe health products off the US market, according to the people familiar with its development. uncertain
it → write → development
The people spoke to The Associated Press on the condition of anonymity to discuss confidential government deliberations. asserted
people → speak → deliberations
The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV. asserted
that → direct → BPC-157
Under normal FDA rules, those chemicals would be considered illegal drugs because they have not gone through the agency’s rigorous review process for safety and effectiveness. asserted
they → consider → safety
According to the document posted online, Kennedy determined the change “advances patient choice and freedom” while protecting people in the United States from peptides sold online that are often made from ingredients of unknown origin and quality. uncertain
that → accord → origin
Kennedy has called himself a “big fan” of peptides and previously described using BPC-157 to treat a muscle injury. asserted
Kennedy → call → injury
Lee Rosebush of the American Academy of Peptide Medicine said in an online post that HHS had taken “a huge step for patient and provider medical freedom.” asserted
HHS → say → freedom
The group, which is not a medical professional society, represents people who prescribe or sell peptides. asserted
who → represent → peptides
The peptide business has caught the attention of major telehealth providers, including Hims & Hers, which recently announced plans to offer wellness peptides once the government changed its policy. asserted
government → catch → policy
Wall Street analysts estimate the market could be worth more than $2 billion. uncertain
market → estimate → ?
Wellness peptides are not FDA approved Some peptides occur naturally in the human body, where they trigger hormones needed for growth, metabolism and healing. asserted
they → approve → growth
Drug companies have brought several to market as medications, including mainstay treatments for diabetes and weight loss. asserted
companies → bring → diabetes
The chemicals subject to the new policy have not been approved as safe and effective by the FDA. asserted
chemicals → approve → FDA
Still, they are promoted online by influencers and celebrities for a range of medical uses, including insomnia, anxiety, inflammatory conditions and migraines. asserted
they → promote → insomnia
Dr. Peter Lurie, a former FDA official, noted that the FDA has already approved rigorously tested drugs for all of those conditions. asserted
FDA → note → conditions
As people “are diverted from those drugs toward this stuff, there will be more unnecessary pain and suffering,” said Lurie, who now leads the nonprofit Center for Science in the Public Interest. asserted
who → divert → Interest
He also questioned the timing of the change, days before the midterm election. asserted
He → question → election
A spokesperson for HHS said the agency is “confronting the risks of black-market peptides” by giving Americans “a more controlled alternative through licensed US compounders.” asserted
agency → say → compounders
It is the latest example of Kennedy reshaping US health policy in the MAHA mold. asserted
Kennedy → reshape → mold
Some of the biggest figures in that movement sell peptide injections and supplements. asserted
Some → sell → injections
The decision is a stark break from past FDA efforts to limit the availability of unproven wellness products, including peptides, stem cell therapies and dietary supplements, that make unsupported medical claims. uncertain
that → limit → claims
But that approach put the agency at odds with Kennedy, who has publicly endorsed the benefits of all of those products. asserted
who → put → products
The policy published Wednesday is a step back from HHS’ original plan, according to two of the people who discussed its development. uncertain
who → publish → development
HHS officials initially wanted the FDA to draft an official regulation that would add BPC-157 and other peptides to a list of drug substances deemed safe for use by compounding pharmacies, specialty businesses that make customized medications. asserted
that → want → medications
FDA officials warned that the agency’s scientific staffers had major safety concerns and would not support a regulation deeming the peptides safe. asserted
peptides → warn → regulation
HHS officials moved to a different approach that directs the FDA not to enforce its rules against pharmacies that compound the substances. asserted
that → move → substances
FDA staffers ultimately provided technical assistance in drafting the HHS plan, including guardrails intended to improve safety, such as requiring pharmacies to use peptide ingredients from FDA-registered factories. asserted
staffers → provide → factories
Additionally, compounders are directed to collect information on side effects for safety analysis and verify the purity of peptides they use. asserted
they → direct → peptides
Lurie pointed out that the FDA, under federal law, does not have the authority to enforce those pharmacy requirements. asserted
FDA → point → requirements
The Alliance for Pharmacy Compounding, which represents specialty pharmacies, said several details need to be clarified — including when the policy takes effect and how it will intersect with state pharmacy boards, who traditionally regulate pharmacists. asserted
who → represent → pharmacists
Decisions over compounding have long rested with the FDA, not HHS Decisions about regulating peptides and compounding pharmacies have almost always come from the FDA, which has an office dedicated to protecting US consumers from unsafe or poor-quality compounded drugs. asserted
which → rest → drugs
The issue of compounding safety became a greater focus for the FDA after a deadly outbreak of fungal meningitis in 2012 was linked to contaminated injections from a Massachusetts compounding pharmacy. asserted
outbreak → become → pharmacy
Once a niche business, compounding has grown into a multibillion-dollar industry, providing customized medications to doctors, clinics and hospitals. asserted
compounding → grow → doctors
It’s extremely rare for HHS to take the lead in drafting policies over the compounding industry, former FDA officials said. asserted
officials → ’ → industry
But federal law technically gives HHS authority over drug regulations, which are then delegated to the FDA. asserted
which → give → FDA
…and 6 more, not listed.
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support